Standout Papers

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease 2022 2026 2023 2024172
  1. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease (2022)
    Brage Brakedal, Christian Dölle et al. Cell Metabolism

Immediate Impact

5 from Science/Nature 55 standout
Sub-graph 1 of 25

Citing Papers

Frailty in Older Adults
2024 Standout
Mitochondrial dysfunction: mechanisms and advances in therapy
2024 Standout
1 intermediate paper

Works of Joseph Diab being referenced

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease
2022 Standout

Author Peers

Author Last Decade Papers Cites
Joseph Diab 66 191 45 65 9 447
Marija Dulović 113 174 18 15 13 453
I. F. Douek 54 91 39 71 8 388
Collin D. Heer 37 158 56 51 13 376
Nicholas H. F. Fine 91 214 25 30 16 501
Renqiang Sun 90 186 37 142 17 450
Sharon O’Neill 66 219 14 15 9 462
Hui-fen Zheng 238 194 39 16 7 482
Chenxia He 39 241 8 13 16 430
Kartini Iskandar 159 274 31 30 9 456
Takeya Kubo 33 276 16 9 11 416

All Works

Loading papers...

Rankless by CCL
2026